These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22750722)

  • 21. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.
    Macauley D; Al-Shamahi A
    IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499
    [No Abstract]   [Full Text] [Related]  

  • 22. Translational research in central nervous system drug discovery.
    Hurko O; Ryan JL
    NeuroRx; 2005 Oct; 2(4):671-82. PubMed ID: 16489374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A role for fMRI in optimizing CNS drug development.
    Borsook D; Becerra L; Hargreaves R
    Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning.
    Morofuji Y; Nakagawa S
    Curr Pharm Des; 2020; 26(13):1466-1485. PubMed ID: 32091330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug repositioning for orphan diseases.
    Sardana D; Zhu C; Zhang M; Gudivada RC; Yang L; Jegga AG
    Brief Bioinform; 2011 Jul; 12(4):346-56. PubMed ID: 21504985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of predictive models in CNS diseases.
    Gomeni R
    Curr Opin Pharmacol; 2014 Feb; 14():23-9. PubMed ID: 24565008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CNS drug development - lost in translation?
    Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
    Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.
    Geerts H; Kennis L
    Future Med Chem; 2014; 6(16):1757-69. PubMed ID: 25574530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
    Pangalos MN; Schechter LE; Hurko O
    Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural modifications that alter the P-glycoprotein efflux properties of compounds.
    Hitchcock SA
    J Med Chem; 2012 Jun; 55(11):4877-95. PubMed ID: 22506484
    [No Abstract]   [Full Text] [Related]  

  • 32. Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.
    Butlen-Ducuing F; Pétavy F; Guizzaro L; Zienowicz M; Haas M; Alteri E; Salmonson T; Corruble E
    Nat Rev Drug Discov; 2016 Nov; 15(12):813-814. PubMed ID: 27895328
    [No Abstract]   [Full Text] [Related]  

  • 33. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
    Rossi T; Braggio S
    Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapeutic modalities to address nondrugable protein interaction targets.
    De Souza EB; Cload ST; Pendergrast PS; Sah DW
    Neuropsychopharmacology; 2009 Jan; 34(1):142-58. PubMed ID: 18754007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
    Yokley BH; Hartman M; Slusher BS
    ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic network modeling and simulation for drug targeting and discovery.
    Kim HU; Sohn SB; Lee SY
    Biotechnol J; 2012 Mar; 7(3):330-42. PubMed ID: 22125297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mining small-molecule screens to repurpose drugs.
    Swamidass SJ
    Brief Bioinform; 2011 Jul; 12(4):327-35. PubMed ID: 21715466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An introduction to adaptive designs and adaptation in CNS trials.
    Dragalin V
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs.
    Raevsky OA; Mukhametov A; Grigorev VY; Ustyugov A; Tsay SC; Jih-Ru Hwu R; Yarla NS; Tarasov VV; Aliev G; Bachurin SO
    Curr Med Chem; 2018; 25(39):5293-5314. PubMed ID: 28933295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.